United Therapeutics Corporation
Bear Case (25th pct.)
-28.4% vs price
Base Case (Median)
-18.6% vs price
Bull Case (75th pct.)
9.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $168.08 | -66.9% | High (40%) |
| PE Comparable | $621.12 | 22.2% | Medium (25%) |
| Growth Trajectory DCF | $895.21 | 76.1% | Medium (20%) |
| Graham Number | $317.16 | -37.6% | Medium (40%) |
| EV/EBITDA | $410.61 | -19.2% | Medium (20%) |
| EV/FCF | $493.45 | -3.0% | Medium (20%) |
| Earnings Power Value | $413.70 | -18.6% | Medium (50%) |
Based on 7 out of 8 methods, UTHR appears fairly valued at the current price of $508.48. The base case fair value of $413.70 implies 18.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.